|

LVIVO-TaVec100 product Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • The First Affiliated Hospital with Nanjing Medical University1

Indications

  • Relapsed/Refractory B-cell Malignancies1
  • Cancer1

Other1 trial

The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.